Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iMATRIX-Atezolizumab
NCT02541604Phase 2Terminated
- Sponsor
- Roche
- Start
- Nov 2015
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in solid tumor, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and 6 more, sponsored by Roche. Primary endpoints: Objective Response Rate up to 42 months, Progression-Free Survival up to 42 months and 5 more. Started Nov 2015; status: terminated.
02
Drugs
atezolizumab
03
Conditions
solid tumorHodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)neuroblastomaAtypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT02541604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02541604.